Paul Damon & Associates, Inc. Abb Vie Inc. Transaction History
Paul Damon & Associates, Inc.
- $209 Billion
- Q3 2025
A detailed history of Paul Damon & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Paul Damon & Associates, Inc. holds 3,094 shares of ABBV stock, worth $723,996. This represents 0.34% of its overall portfolio holdings.
Number of Shares
3,094
Previous 2,725
13.54%
Holding current value
$723,996
Previous $506 Million
41.6%
% of portfolio
0.34%
Previous 0.27%
Shares
3 transactions
Others Institutions Holding ABBV
# of Institutions
4,491Shares Held
1.28BCall Options Held
16.9MPut Options Held
15.2M-
Vanguard Group Inc Valley Forge, PA178MShares$41.6 Billion0.64% of portfolio
-
Black Rock Inc. New York, NY136MShares$31.9 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.8MShares$18.7 Billion0.66% of portfolio
-
Jpmorgan Chase & CO New York, NY56.5MShares$13.2 Billion0.86% of portfolio
-
Morgan Stanley New York, NY41.7MShares$9.75 Billion0.61% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $414B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...